I

Inno-Gene SA
WSE:IGN

Watchlist Manager
Inno-Gene SA
WSE:IGN
Watchlist
Price: 5.04 PLN -0.4% Market Closed
Market Cap: 17.7m PLN
Have any thoughts about
Inno-Gene SA?
Write Note

Inno-Gene SA
Accounts Receivables

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Inno-Gene SA
Accounts Receivables Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Accounts Receivables CAGR 3Y CAGR 5Y CAGR 10Y
I
Inno-Gene SA
WSE:IGN
Accounts Receivables
zł665k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
M
Medicofarma Biotech SA
WSE:MDB
Accounts Receivables
zł422.8k
CAGR 3-Years
248%
CAGR 5-Years
43%
CAGR 10-Years
N/A
R
Ryvu Therapeutics SA
WSE:RVU
Accounts Receivables
zł12.4m
CAGR 3-Years
175%
CAGR 5-Years
N/A
CAGR 10-Years
7%
S
Selvita SA
WSE:SLV
Accounts Receivables
zł72.9m
CAGR 3-Years
12%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Inno-Gene SA
Glance View

Market Cap
17.7m PLN
Industry
Life Sciences Tools & Services

Inno Gene SA engages in the management of startup biotechnology companies. The company is headquartered in Poznan, Woj. Wielkopolskie. The company went IPO on 2011-02-08. Inno-Gene SA’s portfolio comprises of Centrum Badan DNA Sp. z o.o., a company that provides services in the field of genetic medical diagnostics, including microbiological diagnosis of infection and the suitability of human congenital diseases using tests performed on DNA microarray technology. On March 22, 2013, the Company established a new subsidiary, Centrum Edukacji Bio-Medycznej Sp. z o.o. On April 11, 2013, the Company established two new indirect subsidiaries, Genomix Sp. z o.o. and Madgenetix Sp. z o.o. In addition, it operates through VitainSillica Sp z o o.

IGN Intrinsic Value
2.03 PLN
Overvaluation 60%
Intrinsic Value
Price
I

See Also

What is Inno-Gene SA's Accounts Receivables?
Accounts Receivables
665k PLN

Based on the financial report for Jun 30, 2024, Inno-Gene SA's Accounts Receivables amounts to 665k PLN.

Back to Top